Cover storyPharma workforce transformation is accelerating in 2026, driven by AI adoption, the patent cliff, and biologics growth reshaping hiring priorities.
CTGTAC votes 9-3 against deramiocel for DMD cardiomyopathy; FDA decision due August 22, 2026 on BLA 125842.
FDA grants accelerated approval to BMS's iberdomide (Zenbexus) for RRMM, triggering mandatory REMS enrollment for specialty pharmacies and distributors.
Eton Pharmaceuticals reports 99% revenue growth in Q2 2026 while advancing FDA Fast Track, a PAS filing, and a 2027 NDA target across its rare disease pipeline.
Eledon secures FDA End-of-Phase 2 alignment for tegoprubart, setting the regulatory and CMC framework for a 600-patient global Phase 3 kidney transplant trial due late 2026.
Latest edition
Interview20260622153015.png&w=1920&q=75&dpl=dpl_9xUZQSvr7qh8u3ierG8JmijXnhDf)
Interview
Interview
Podcast
Sep 28
Nov 18
Feb 03From native content to event partnerships, we help brands earn the attention of a hard-to-reach, senior audience — without breaking the reading experience.
See partnership options →Explore expert-led guides crafted for pharma professionals. Log in to download and stay ahead.
Join thousands of pharma professionals getting our sharpest reporting, briefings and guides — free.
20260804110923.webp&w=1920&q=75&dpl=dpl_9xUZQSvr7qh8u3ierG8JmijXnhDf)
